Epirubicin
Topoisomerase Inhibitor
DB00445
Approved Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
2
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity.
Details
DrugBank ID
DB00445 ↗
Approval Date
1999-09-15
Molecular Weight
543.5193 g/mol
Drug Class
Topoisomerase Inhibitor
ATC Codes
L01DB03
Synonyms
4'-Epiadriamycin, Epiadriamycin, Epirubicin
PubChem
CID: 41867 ↗
ChEMBL
CHEMBL417 ↗
SMILES
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
ADMET Profile
Computing properties…